Global Long Acting Drug Delivery Market Overview:
Long-acting drug delivery is a development in pharmaceutical technology to minimize the disadvantages of other routes of administration such as oral, transdermal, and injectable administration. Long-acting drug shipping systems, such as implants and mixture products, are an an increasing number of famous method for sustained drug delivery, imparting the achievable for centered drug release, decrease dosage requirements, and accelerated affected person compliance. A well-designed drug-eluting machine can positively influence bioavailability, stability, and pharmacokinetics of an energetic pharmaceutical ingredient (API) whilst additionally supplying attainable mental property and life-cycle administration opportunities.
Growth Drivers
- Growing cases of chronic diseases
- An increasingly popular approach for sustained drug delivery, offering the potential for targeted drug release, lower dosage requirements, and improved patient compliance
- The high growth of this segment is attributed to the rising demand for biologics
Roadblocks
- High cost of the product
- Lack of medication compliance which detrimental to treatment response
Opportunities
- Technological advancement in new product launches
- Development of long-acting drug delivery platform to treat chronic disorders
- Rapidly developing bespoke ex vivo disease models to test the implant performance
- Rapid technological advancements in the field of injectable drug delivery that create new opportunities
Challenges
- An increasing number of diseases such as cancer
Competitive Landscape:
Companies in the market are concentrating on pharmaceutical and drug delivery. The new product launch and high growth in the healthcare market are expected to offer significant growth opportunities for the market during the forecast period. North America, the fastest-growing country in the region due to the increased R&D investments, rise in healthcare expenditure, and government initiatives to support the development of advanced diagnostic procedures.
Some of the key players profiled in the report are National Center for Biotechnology Information (United States), Lubrizol Life Science Health - CDMO Division (United States), West Pharmaceutical Services (United States), Celanese (United States), DelsiTech Oy (Finland), Gerresheimer AG (Germany), Baxter International, Inc. (United States), Pfizer, Inc. (United States), Alkermes Plc. (Irland), Becton Dickinson and Company (United States), Eli Lilly and Company (United States), Schott AG (Germany), Terumo Corporation (Japan), Unilife Corporation (United States), Endocyte (United States) and Genentech Inc. (United States). Additionally, following companies can also be profiled that are part of our coverage like Elcam Medical (Italy) and Teva Pharmaceuticals Industries Ltd. (Israel). Analyst at AMA Research see United States Players to retain maximum share of Global Long Acting Drug Delivery market by 2027. Considering Market by Injectable, the sub-segment i.e. Sterile Liquid and Powder Filling will boost the Long Acting Drug Delivery market. Considering Market by End-Use Industries , the sub-segment i.e. Pharmaceuticals will boost the Long Acting Drug Delivery market. Considering Market by Implants, the sub-segment i.e. Extensive Statistical-based Modelling will boost the Long Acting Drug Delivery market.
6 Nov, 2017: West Pharmaceutical Services, Inc. presented a new extension of SMARTDOSE drug delivery platform. This platform includes wearable injectors and it allows for up to 10 mL of volume to be injected in easy-to-use, wearable formats. and 19 Oct, 2021: West Pharmaceutical Services, Inc. introduced the DeltaCube Modeling Platform as well as the new NovaGuard SA Pro Safety System. This system is designed to help developers to make more confident decisions about their container closure systems.
What Can be Explored with the Long Acting Drug Delivery Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Long Acting Drug Delivery Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Long Acting Drug Delivery
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Long Acting Drug Delivery market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Long Acting Drug Delivery market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Healthcare Industry/Centres, Research & Development, Medical Centres, Manufacturers, Pharmaceutical Scientists, Biomedical Engineers and Clinicians.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.